Logo

Larimar Therapeutics, Inc.

LRMR

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.ā€ā€ā€Žā€¦ read more

Healthcare

Biotechnology

12 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$3.98

Price

+4.19%

$0.16

Market Cap

$413.454m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$166.005m

-0.2%

1y CAGR

-74.6%

3y CAGR

-57.1%

5y CAGR
EPS

-$2.10

+7.5%

1y CAGR

-40.5%

3y CAGR

-21.2%

5y CAGR
Book Value

$158.033m

$208.511m

Assets

$50.478m

Liabilities

$3.779m

Debt
Debt to Assets

1.8%

-

Debt to EBITDA
Free Cash Flow

-$131.317m

-15.9%

1y CAGR

-62.3%

3y CAGR

-52.1%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases